Stock Evaluator: Pasithea Therapeutics Corp. (KTTA)

Pasithea Therapeutics Corp. KTTA

$0.50 -0.02 -4.21%
November 16, 2026 4:00:01 PM EST November 10, 2021 Volume: 944,209
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Commentary & Analysis


Financial Summary

Share Statistics KTTA Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $16.7 $202.9 10%
Shares Out (Mil) 33.4 55.4 39%
Institutional Ownership 96.4% 92.9% 69%
Float (Mil) 23.1 40.7 31%
Beta na 1.04 na
Avg Daily Volume (000s) 2,968 566 85%
Price Change
(52-week)
(28.9%) 41.0% 31%
Growth KTTA Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) na (10.3%) na
EPS (5yr) na 15.8% na
Dividends (5yr) na 0.0% na
Cash Flow (5yr) 45.6% (15.7%) 92%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 1 1 1
Current EPS ($0.250) ($0.760) ($0.460)
Month Ago EPS ($0.250) ($0.760) ($0.460)
# Rev Up 0 1 1
# Rev Down 1 0 0
Three Months Ago EPS ($0.250) ($0.760) ($0.460)
Year/Year Chg 25.0% (73.8%) (81.1%)
Financials KTTA Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $39 na
Net Income (TTM) (Mil) ($25) ($44) 22%
EPS (TTM) ($0.967) ($1.400) 21%
Operating Cash Flow (TTM) (Mil) ($19) ($34) 15%
Net Cash Flow (TTM) (Mil) na ($1) na
Long-Term Debt (Q1) (Mil) $0 $4 0%
Enterprise Value (Q1) (Mil) ($24) $144 1%
Valuation KTTA Industry
Median
Percentile
(All Stocks)
P/B 0.38 1.97 8%
P/E na 17.5 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.8 na
Ratios KTTA Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.6% na
Net Margin na (50.6%) na
ROA (82.6%) (47.4%) 7%
ROE (88.8%) (53.5%) 10%
Liabilities to Assets 5.9% 29.7% 3%
F-Score 3 3 18%

Pasithea Therapeutics Corp. did not pass any screens on 11/16/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors